Immorta Bio Inc., a company focused on longevity and regenerative medicine, has announced a significant breakthrough in the treatment of liver failure. The company is developing personalized stem cell technologies that show great promise in combating various diseases of aging.
Immorta Bio’s research pipeline includes Personalized Regenerative Cells (PRCs), Personalized Mesenchymal Stem Cells (pMSCs), and Personalized Progenitor Cells (PPCs). These stem cells are pluripotent, meaning they can generate younger versions of any cell type in the body. This capability is crucial in treating diseases of aging by replacing damaged tissues with healthy, young cells.
The company’s innovative approach uses organ-specific molecules and “injury signals” to transform Personalized Regenerative Cells into organ-specific cells that can repair and rejuvenate damaged tissues.
This technology aims to improve the effectiveness of stem cell therapies by pre-differentiating the cells in the lab before administering them to patients, potentially leading to higher levels of cell engraftment and better therapeutic outcomes.
Dr. Boris Reznik, Chairman and CEO of Immorta Bio, emphasized the company’s focus on developing these personalized stem cell platforms to address the root causes of aging and increase longevity. The initial focus is on achieving FDA clearance to treat heart failure, liver failure, and multiple organ failure.
Additionally, Immorta Bio plans to offer banking services for Personalized Regenerative Cells for both healthy individuals and patients, ensuring a readily available supply of these cells for future therapeutic needs.
This breakthrough represents a significant step forward in the field of regenerative medicine and provides new hope for patients suffering from liver failure and other age-related conditions.
For more detailed information, you can visit the original press release on BioSpace (BioSpace) (Treating Diseases of Aging).